Corvus Pharmaceuticals, Inc. financial data

Symbol
CRVS on Nasdaq
Industry
Pharmaceutical Preparations
Location
863 Mitten Road, Suite 102, Burlingame, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 386 % -6.26%
Debt-to-equity 20.6 % -1.01%
Return On Equity -54 % +24.2%
Return On Assets -44.8 % +24.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62.6M shares +27.7%
Common Stock, Shares, Outstanding 62.6M shares +27.9%
Entity Public Float 84.2M USD +146%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 59.7M shares +25.7%
Weighted Average Number of Shares Outstanding, Diluted 59.7M shares +25.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 16.2M USD -29.8%
General and Administrative Expense 7.25M USD -1.12%
Operating Income (Loss) -23.4M USD +22.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -22.6M USD +42%
Earnings Per Share, Basic -0.44 USD/shares +47.6%
Earnings Per Share, Diluted -0.44 USD/shares +47.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.8M USD +93.8%
Cash, Cash Equivalents, and Short-term Investments 47.2M USD +27.6%
Accounts Receivable, after Allowance for Credit Loss, Current 35K USD
Other Assets, Current 240K USD +76.5%
Assets, Current 48.3M USD +27.3%
Property, Plant and Equipment, Net 192K USD -34.7%
Operating Lease, Right-of-Use Asset 578K USD -65.8%
Other Assets, Noncurrent 129K USD 0%
Assets 64.6M USD +11.2%
Accounts Payable, Current 1.21M USD -42.2%
Employee-related Liabilities, Current 683K USD -15.1%
Liabilities, Current 13.3M USD +69.7%
Operating Lease, Liability, Noncurrent 354K USD -79%
Liabilities 13.3M USD +55.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.36M USD +0.95%
Retained Earnings (Accumulated Deficit) -345M USD -7.02%
Stockholders' Equity Attributable to Parent 51.2M USD +3.52%
Liabilities and Equity 64.6M USD +11.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.16M USD +36.4%
Net Cash Provided by (Used in) Investing Activities 4.6M USD
Common Stock, Shares Authorized 290M shares 0%
Common Stock, Shares, Issued 62.6M shares +27.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.16M USD -47.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 14.8M USD +93.8%
Deferred Tax Assets, Valuation Allowance 83M USD +8.71%
Deferred Tax Assets, Gross 83.3M USD +8.25%
Operating Lease, Liability 700K USD
Payments to Acquire Property, Plant, and Equipment 34K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -22.6M USD +44.5%
Lessee, Operating Lease, Liability, to be Paid 717K USD
Property, Plant and Equipment, Gross 4.79M USD -2.86%
Operating Lease, Liability, Current 700K USD -46.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.39M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.43M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 280K USD -49.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.43M USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 59.3M USD +5.86%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 12.8M USD +0.81%
Operating Lease, Payments 1.87M USD +6.75%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 23K USD -59.6%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 2.58M USD +11.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%